Opendata, web and dolomites

VISIOCYT

VISIOCYT SCREENING: A DISRUPTIVE ARTIFICIAL INTELLIGENCE SOLUTION FOR BLADDER CANCER SCREENING

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VISIOCYT project word cloud

Explore the words cloud of the VISIOCYT project. It provides you a very rough idea of what is the project "VISIOCYT" about.

vitadx    58    disease       cagr    diagnostic    former    workers    treatment    locations    readily    regular    people    risk    patients    fast    symptoms    few    2023    laboratories    diagnosis    clinical    reproducible    survival    skills    classified    time    besides    detection    software    invasive    solution    tool    smokers    rate    vitro    grade    exposed    tumour    automated    intelligence    2018    background    combines    chemicals    cheaper    expertise    programs    95    global    visiocyt    cancer    algorithms    artificial    labs    drops    centralized    standard    deaths    device    certain    images    incidence    living    appear    gt    65    market    solutions    bladder    lt    identification    predict    image    stages    equipped    dying    ing    price    french    accuracy    customers    ivd    200    billion    polluted    screening    stage    throughput    almost    5th    easier    scientific    medical    sme    cytology    depends    tumours    75    perform       business   

Project "VISIOCYT" data sheet

The following table provides information about the project.

Coordinator
VITADX INTERNATIONAL 

Organization address
address: 74 F RUE DE PARIS
city: RENNES
postcode: 35000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://vitadx.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VITADX INTERNATIONAL FR (RENNES) coordinator 50˙000.00

Map

 Project objective

Bladder cancer is the 5th most common cancer in Europe, with almost 200,000 new cases and 65,000 deaths estimated in 2018. People at high risk for developing this disease include smokers, former smokers, people living in polluted areas, and workers exposed to certain chemicals. The risk of dying from bladder cancer depends on the time of diagnosis and the tumour’s grade: the 5-year survival rate is >95% in early stage cancer, but it drops to <5% in late stage tumours. Besides increased survival, the identification of bladder cancer at its early stages is also associated with easier, less invasive, and cheaper treatment. Given the importance of early detection and the high incidence of bladder cancer, screening programs for this disease are needed. However, there is no screening tool currently available for bladder cancer. As a solution, VitaDX is developing VisioCyt Screening: a software that combines artificial intelligence algorithms with standard cytology analysis to predict with high accuracy the presence of bladder cancer in patients, even before symptoms appear. Being a software that analyses images obtained through regular clinical procedures, VisioCyt Screening can be readily implemented in centralized labs, resulting in a fast, easy-to-use, reproducible, automated, and high-throughput solution at a low price. VisioCyt Screening can be classified as an in-vitro diagnostic (IVD) medical device. The global IVD market was estimated at €58 billion in 2018, and is expected to reach €75.2 billion by 2023, with a CAGR rate of 5.2%. In this market, centralized laboratories, which perform large numbers of analyses in few locations and are equipped with the automated systems required by the VisioCyt solution, represent the most relevant target users and customers for VitaDX. VitaDX is a French SME that combines a strong scientific and clinical background with software and image processing skills and business expertise to develop new diagnostic solutions for cancer.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VISIOCYT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VISIOCYT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

EASY-Diabetes (2019)

Individualised and Equitable Care of Type 2 Diabetes

Read More